The role of advanced glycation end products in retinal microvascular leukostasis

Tara Moore, Johnny Moore, Y Kaji, N Frizzell, T Usui, V Poulaki, IL Campbell, AW Stitt, TA Gardiner, DB Archer, APPACEIT Pathog

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

PURPOSE. A critical event in the pathogenesis of diabetic retinopathy is the inappropriate adherence of leukocytes to the retinal capillaries. Advanced glycation end-products (AGES) are known to play a role in chronic inflammatory processes, and the authors postulated that these adducts may play a role in promoting pathogenic increases in proinflammatory pathways within the retinal microvasculature. METHODS. Retinal microvascular endothelial cells (RMECs) were treated with glycoaldehyde-modified albumin (AGE-Alb) or unmodified albumin (Alb). NFkappaB DNA binding was measured by electromobility shift assay (EMSA) and quantified with an ELISA. In addition, the effect of AGES on leukocyte adhesion to endothelial cell monolayers was investigated. Further studies were performed in an attempt to confirm that this was AGE-induced adhesion by co-incubation of AGE-treated cells with soluble receptor for AGE (sRAGE). Parallel in vivo studies of nondiabetic mice assessed the effect of intraperitoneal delivery of AGE-Alb on ICAM-I mRNA expression, NFkappaB DNA-binding activity, leukostasis, and blood-retinal barrier breakdown. RESULTS. Treatment with AGE-Alb significantly enhanced the DNA-binding activity of NFkappaB (P = 0.0045) in retinal endothelial cells (RMECs) and increased the adhesion of leukocytes to RMEC monolayers (P = 0.04). The latter was significantly reduced by co-incubation with sRAGE (P < 0.01). Mice infused with AGE-Alb demonstrated a 1.8-fold increase in ICAM-1 mRNA when compared with control animals (P < 0.001, n = 20) as early as 48 hours, and this response remained for 7 days of treatment. Quantification of retinal NFkappaB demonstrated a threefold increase with AGE-Alb infusion in comparison to control levels (AGE Alb versus Alb, 0.23 vs. 0.076, P < 0.001, n = 10 mice). AGE-Alb treatment of mice also caused a significant increase in leukostasis in the retina (AGE-Alb versus Alb, 6.89 vs. 2.53, n = 12, P < 0.05) and a statistically significant increase in breakdown of the blood-retinal barrier (AGE Alb versus Alb, 8.2 vs. 1.6 n = 10, P < 0.001). CONCLUSIONS. AGES caused upregulation of NF&kappa;B in the retinal microvascular endothelium and an AGE-specific increase in leukocyte adhesion in vitro was also observed. In addition, increased leukocyte adherence in vivo was demonstrated that was accompanied by blood-retinal barrier dysfunction. These findings add further evidence to the thinking that AGES may play an important role in the pathogenesis of diabetic retinopathy.
LanguageEnglish
Pages4457-4464
JournalINVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
Volume44
Issue number10
DOIs
Publication statusPublished - 1 Oct 2003

Fingerprint

Leukostasis
Advanced Glycosylation End Products
Albumins
Blood-Retinal Barrier
Leukocytes
Endothelial Cells
Diabetic Retinopathy
DNA
Messenger RNA

Cite this

Moore, T., Moore, J., Kaji, Y., Frizzell, N., Usui, T., Poulaki, V., ... Pathog, APPACEIT. (2003). The role of advanced glycation end products in retinal microvascular leukostasis. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 44(10), 4457-4464. https://doi.org/10.1167/iovs.02-1063
Moore, Tara ; Moore, Johnny ; Kaji, Y ; Frizzell, N ; Usui, T ; Poulaki, V ; Campbell, IL ; Stitt, AW ; Gardiner, TA ; Archer, DB ; Pathog, APPACEIT. / The role of advanced glycation end products in retinal microvascular leukostasis. In: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2003 ; Vol. 44, No. 10. pp. 4457-4464.
@article{216709c547d945e398096b96f1fff30c,
title = "The role of advanced glycation end products in retinal microvascular leukostasis",
abstract = "PURPOSE. A critical event in the pathogenesis of diabetic retinopathy is the inappropriate adherence of leukocytes to the retinal capillaries. Advanced glycation end-products (AGES) are known to play a role in chronic inflammatory processes, and the authors postulated that these adducts may play a role in promoting pathogenic increases in proinflammatory pathways within the retinal microvasculature. METHODS. Retinal microvascular endothelial cells (RMECs) were treated with glycoaldehyde-modified albumin (AGE-Alb) or unmodified albumin (Alb). NFkappaB DNA binding was measured by electromobility shift assay (EMSA) and quantified with an ELISA. In addition, the effect of AGES on leukocyte adhesion to endothelial cell monolayers was investigated. Further studies were performed in an attempt to confirm that this was AGE-induced adhesion by co-incubation of AGE-treated cells with soluble receptor for AGE (sRAGE). Parallel in vivo studies of nondiabetic mice assessed the effect of intraperitoneal delivery of AGE-Alb on ICAM-I mRNA expression, NFkappaB DNA-binding activity, leukostasis, and blood-retinal barrier breakdown. RESULTS. Treatment with AGE-Alb significantly enhanced the DNA-binding activity of NFkappaB (P = 0.0045) in retinal endothelial cells (RMECs) and increased the adhesion of leukocytes to RMEC monolayers (P = 0.04). The latter was significantly reduced by co-incubation with sRAGE (P < 0.01). Mice infused with AGE-Alb demonstrated a 1.8-fold increase in ICAM-1 mRNA when compared with control animals (P < 0.001, n = 20) as early as 48 hours, and this response remained for 7 days of treatment. Quantification of retinal NFkappaB demonstrated a threefold increase with AGE-Alb infusion in comparison to control levels (AGE Alb versus Alb, 0.23 vs. 0.076, P < 0.001, n = 10 mice). AGE-Alb treatment of mice also caused a significant increase in leukostasis in the retina (AGE-Alb versus Alb, 6.89 vs. 2.53, n = 12, P < 0.05) and a statistically significant increase in breakdown of the blood-retinal barrier (AGE Alb versus Alb, 8.2 vs. 1.6 n = 10, P < 0.001). CONCLUSIONS. AGES caused upregulation of NF&kappa;B in the retinal microvascular endothelium and an AGE-specific increase in leukocyte adhesion in vitro was also observed. In addition, increased leukocyte adherence in vivo was demonstrated that was accompanied by blood-retinal barrier dysfunction. These findings add further evidence to the thinking that AGES may play an important role in the pathogenesis of diabetic retinopathy.",
author = "Tara Moore and Johnny Moore and Y Kaji and N Frizzell and T Usui and V Poulaki and IL Campbell and AW Stitt and TA Gardiner and DB Archer and APPACEIT Pathog",
year = "2003",
month = "10",
day = "1",
doi = "10.1167/iovs.02-1063",
language = "English",
volume = "44",
pages = "4457--4464",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
number = "10",

}

Moore, T, Moore, J, Kaji, Y, Frizzell, N, Usui, T, Poulaki, V, Campbell, IL, Stitt, AW, Gardiner, TA, Archer, DB & Pathog, APPACEIT 2003, 'The role of advanced glycation end products in retinal microvascular leukostasis', INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 44, no. 10, pp. 4457-4464. https://doi.org/10.1167/iovs.02-1063

The role of advanced glycation end products in retinal microvascular leukostasis. / Moore, Tara; Moore, Johnny; Kaji, Y; Frizzell, N; Usui, T; Poulaki, V; Campbell, IL; Stitt, AW; Gardiner, TA; Archer, DB; Pathog, APPACEIT.

In: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, Vol. 44, No. 10, 01.10.2003, p. 4457-4464.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The role of advanced glycation end products in retinal microvascular leukostasis

AU - Moore, Tara

AU - Moore, Johnny

AU - Kaji, Y

AU - Frizzell, N

AU - Usui, T

AU - Poulaki, V

AU - Campbell, IL

AU - Stitt, AW

AU - Gardiner, TA

AU - Archer, DB

AU - Pathog, APPACEIT

PY - 2003/10/1

Y1 - 2003/10/1

N2 - PURPOSE. A critical event in the pathogenesis of diabetic retinopathy is the inappropriate adherence of leukocytes to the retinal capillaries. Advanced glycation end-products (AGES) are known to play a role in chronic inflammatory processes, and the authors postulated that these adducts may play a role in promoting pathogenic increases in proinflammatory pathways within the retinal microvasculature. METHODS. Retinal microvascular endothelial cells (RMECs) were treated with glycoaldehyde-modified albumin (AGE-Alb) or unmodified albumin (Alb). NFkappaB DNA binding was measured by electromobility shift assay (EMSA) and quantified with an ELISA. In addition, the effect of AGES on leukocyte adhesion to endothelial cell monolayers was investigated. Further studies were performed in an attempt to confirm that this was AGE-induced adhesion by co-incubation of AGE-treated cells with soluble receptor for AGE (sRAGE). Parallel in vivo studies of nondiabetic mice assessed the effect of intraperitoneal delivery of AGE-Alb on ICAM-I mRNA expression, NFkappaB DNA-binding activity, leukostasis, and blood-retinal barrier breakdown. RESULTS. Treatment with AGE-Alb significantly enhanced the DNA-binding activity of NFkappaB (P = 0.0045) in retinal endothelial cells (RMECs) and increased the adhesion of leukocytes to RMEC monolayers (P = 0.04). The latter was significantly reduced by co-incubation with sRAGE (P < 0.01). Mice infused with AGE-Alb demonstrated a 1.8-fold increase in ICAM-1 mRNA when compared with control animals (P < 0.001, n = 20) as early as 48 hours, and this response remained for 7 days of treatment. Quantification of retinal NFkappaB demonstrated a threefold increase with AGE-Alb infusion in comparison to control levels (AGE Alb versus Alb, 0.23 vs. 0.076, P < 0.001, n = 10 mice). AGE-Alb treatment of mice also caused a significant increase in leukostasis in the retina (AGE-Alb versus Alb, 6.89 vs. 2.53, n = 12, P < 0.05) and a statistically significant increase in breakdown of the blood-retinal barrier (AGE Alb versus Alb, 8.2 vs. 1.6 n = 10, P < 0.001). CONCLUSIONS. AGES caused upregulation of NF&kappa;B in the retinal microvascular endothelium and an AGE-specific increase in leukocyte adhesion in vitro was also observed. In addition, increased leukocyte adherence in vivo was demonstrated that was accompanied by blood-retinal barrier dysfunction. These findings add further evidence to the thinking that AGES may play an important role in the pathogenesis of diabetic retinopathy.

AB - PURPOSE. A critical event in the pathogenesis of diabetic retinopathy is the inappropriate adherence of leukocytes to the retinal capillaries. Advanced glycation end-products (AGES) are known to play a role in chronic inflammatory processes, and the authors postulated that these adducts may play a role in promoting pathogenic increases in proinflammatory pathways within the retinal microvasculature. METHODS. Retinal microvascular endothelial cells (RMECs) were treated with glycoaldehyde-modified albumin (AGE-Alb) or unmodified albumin (Alb). NFkappaB DNA binding was measured by electromobility shift assay (EMSA) and quantified with an ELISA. In addition, the effect of AGES on leukocyte adhesion to endothelial cell monolayers was investigated. Further studies were performed in an attempt to confirm that this was AGE-induced adhesion by co-incubation of AGE-treated cells with soluble receptor for AGE (sRAGE). Parallel in vivo studies of nondiabetic mice assessed the effect of intraperitoneal delivery of AGE-Alb on ICAM-I mRNA expression, NFkappaB DNA-binding activity, leukostasis, and blood-retinal barrier breakdown. RESULTS. Treatment with AGE-Alb significantly enhanced the DNA-binding activity of NFkappaB (P = 0.0045) in retinal endothelial cells (RMECs) and increased the adhesion of leukocytes to RMEC monolayers (P = 0.04). The latter was significantly reduced by co-incubation with sRAGE (P < 0.01). Mice infused with AGE-Alb demonstrated a 1.8-fold increase in ICAM-1 mRNA when compared with control animals (P < 0.001, n = 20) as early as 48 hours, and this response remained for 7 days of treatment. Quantification of retinal NFkappaB demonstrated a threefold increase with AGE-Alb infusion in comparison to control levels (AGE Alb versus Alb, 0.23 vs. 0.076, P < 0.001, n = 10 mice). AGE-Alb treatment of mice also caused a significant increase in leukostasis in the retina (AGE-Alb versus Alb, 6.89 vs. 2.53, n = 12, P < 0.05) and a statistically significant increase in breakdown of the blood-retinal barrier (AGE Alb versus Alb, 8.2 vs. 1.6 n = 10, P < 0.001). CONCLUSIONS. AGES caused upregulation of NF&kappa;B in the retinal microvascular endothelium and an AGE-specific increase in leukocyte adhesion in vitro was also observed. In addition, increased leukocyte adherence in vivo was demonstrated that was accompanied by blood-retinal barrier dysfunction. These findings add further evidence to the thinking that AGES may play an important role in the pathogenesis of diabetic retinopathy.

U2 - 10.1167/iovs.02-1063

DO - 10.1167/iovs.02-1063

M3 - Article

VL - 44

SP - 4457

EP - 4464

JO - Investigative Ophthalmology and Visual Science

T2 - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 10

ER -